Researchers at the University of Sydney have completed the most comprehensive review of opioid medications ever undertaken—and the findings challenge everything we thought we knew about these commonly prescribed painkillers. After analyzing 59 systematic reviews covering more than 50 acute pain conditions across both children and adults, the team discovered that opioids such as codeine, morphine, oxycodone, and tramadol often provide only minimal relief and no meaningful benefit for many of the conditions they're routinely prescribed to treat.
The implications are profound for millions of patients globally. Opioids have long been considered the default "go-to" treatment for acute pain, a belief so entrenched that doctors and patients alike rarely question their necessity. Yet this landmark analysis, published in the journal Drugs, reveals a more complicated reality: for most acute pain conditions, opioids deliver pain relief that lasts only a few hours and barely outperforms placebo. Associate Professor Christina Abdel Shaheed from the University of Sydney's School of Public Health put it plainly: "Opioids did not provide large or lasting pain relief compared with placebo for the vast majority of acute pain conditions."
The research identified specific conditions where opioids do show modest benefit—stomach pain, pain following dental surgery, ear procedures, traumatic limb injuries, childbirth, caesarean delivery, and bunion removal. But the list of conditions where they offer no advantage is equally striking: certain types of limb surgery, kidney stone pain, pain after tonsil removal, and even pain experienced by newborns on assisted breathing devices. For other conditions including heart-related pain and pain after hysterectomy, the benefits were inconsistent.
What makes the findings particularly urgent is the safety concern. Beyond their limited effectiveness, opioids carry significant risks when used for acute musculoskeletal pain, traumatic limb injuries, and some post-surgical pain—increasing the likelihood of nausea, vomiting, and other side effects. More troubling still, dependence can develop remarkably quickly. "Persistent use of opioid medicines can develop quickly following first time use, sometimes within days," noted Dr. Stephanie Mathieson, co-first author from the University of Sydney's Institute for Musculoskeletal Health. Regular use, even for acute pain, carries risks of tolerance, misuse, overdose, and overdose-related death. The researchers also flagged a critical gap: many clinical trials failed to adequately report side effects, suggesting the true harms may be worse than current data shows.
The timing of this review couldn't be more significant. Communities worldwide have grappled with opioid addiction and overdose epidemics for years, making evidence-based prescribing practices essential. The message from this research is clear: doctors should prescribe opioids judiciously—using the lowest effective dose for the shortest possible duration. Patients, too, deserve transparency about potential harms when these medications are offered.
Co-first author Associate Professor Joshua Zadro emphasized the broad reach of these findings: they matter for patients across all ages experiencing acute pain, for the doctors treating them, and for policymakers regulating medication safety. By showing that opioid benefits are generally small, short-lived, and sometimes harmful, this review opens space for conversations about better, safer alternatives to pain management—and invites healthcare systems to rethink practices that have persisted longer than evidence justifies.